drugset

drugset / Trial / NCT07641634

A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.

NCT07641634 ↗

Phase 1/2 Recruiting 44 enrolled Prolium Bioscience, Inc

RandomizedSequentialTriple-blindTreatment

Summary

A two-part study of PRO-203 administered subcutaneously in healthy adult volunteers and participants with Systemic Sclerosis (SSc).

Timeline

Start: 2025-10-27
Primary completion: 2027-01
Completion: 2028-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PRO-203	Unknown	—	Subcutaneous

Indications